ERBB2 and breast carcinoma: The SUMMIT trial (Hyman et al., 2018) demonstrates that neratinib exhibits maximum activity in patients with HER2 mutant breast cancer, with missense mutations involving extracellular and kinase domains, as well as kinase domain insertions.